It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy

p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR)

(2021) Maya Maor-Nof et al.   CELL

Viral strategies for circumventing p53

(2021) Camila Martin Cardozo et al.   CURRENT OPINION IN ONCOLOGY

Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice

(2021) Timothy J. Humpton et al.   GENES & DEVELOPMENT

Distinct mechanisms control genome recognition by p53 at its target genes linked to different cell fates

(2021) Marina Farkas et al.   Nature Communications

Hypothermia effectively treats tumors with temperature-sensitive p53 mutations

(2021) Junhao Lu et al.   CANCER RESEARCH

Trends in peptide drug discovery

(2021) Markus Muttenthaler et al.   NATURE REVIEWS DRUG DISCOVERY

Proteogenomics drives therapeutic hypothesis generation for precision oncology

(2021) Jonathan T. Lei et al.   BRITISH JOURNAL OF CANCER

Widespread displacement of DNA‐ and RNA‐binding factors underlies toxicity of arginine‐rich cell‐penetrating peptides

(2021) Vanesa Lafarga et al.   EMBO JOURNAL

PRMT1 promotes the tumor suppressor function of p14 ARF and is indicative for pancreatic cancer prognosis

(2021) Antje Repenning et al.   EMBO JOURNAL

The roles and regulation of MDM2 and MDMX: it is not just about p53

(2021) Alyssa M. Klein et al.   GENES & DEVELOPMENT

Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence

(2021) Zhong Wu et al.   NATURE GENETICS

Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand

(2021) Parasvi S. Patel et al.   ONCOGENE

p53 and Tumor Suppression: It Takes a Network

(2021) Anthony M. Boutelle et al.   TRENDS IN CELL BIOLOGY

CDKN2A Deletion in Melanoma Excludes T Cell Infiltration by Repressing Chemokine Expression in a Cell Cycle-Dependent Manner

(2021) Zhen Zhu et al.   Frontiers in Oncology

Valosin-Containing Protein Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth

(2021) Jieqiong Wang et al.   CANCER RESEARCH

Proteogenomic characterization of pancreatic ductal adenocarcinoma

(2021) Liwei Cao et al.   CELL

A proteogenomic portrait of lung squamous cell carcinoma

(2021) Shankha Satpathy et al.   CELL

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

(2021) Elio Adib et al.   CLINICAL CANCER RESEARCH

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53

(2021) Mansoor N Saleh et al.   CLINICAL CANCER RESEARCH

Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration

(2021) Francisco J. Sánchez-Rivera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer

(2021) Xiaoyu Zhao et al.   CANCER RESEARCH

A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing

(2021) Sanju Sinha et al.   Nature Communications

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

(2021) Stanley I. Gutiontov et al.   Scientific Reports

The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity

(2021) Jianhuang Lin et al.   Cancer Immunology Research

MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling

(2020) Divya Venkatesh et al.   GENES & DEVELOPMENT

Top 10 Challenges in Cancer Immunotherapy

(2020) Priti S. Hegde et al.   IMMUNITY

Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model

(2020) Nilay S. Sethi et al.   NATURE GENETICS

SENEBLOC, a long non-coding RNA suppresses senescence via p53-dependent and independent mechanisms

(2020) Cheng Lin Xu et al.   NUCLEIC ACIDS RESEARCH

Stromal-MDM2 Promotes Lung Cancer Cell Invasion through Tumor–Host Feedback Signaling

(2020) Iris Kamer et al.   MOLECULAR CANCER RESEARCH

Cas9 activates the p53 pathway and selects for p53-inactivating mutations

(2020) Oana M. Enache et al.   NATURE GENETICS

Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies

(2020) Xia-qing Xu et al.   ACTA PHARMACOLOGICA SINICA

Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer

(2020) Leo Yamada et al.   Gastric Cancer

MDM2 inhibition: an important step forward in cancer therapy

(2020) Marina Konopleva et al.   LEUKEMIA

The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic

(2020) Eliran Kadosh et al.   NATURE

Manumycin polyketides act as molecular glues between UBR7 and P53

(2020) Yosuke Isobe et al.   Nature Chemical Biology

p53 programmes plough on

(2020) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities

(2020) Sejin Oh et al.   Nature Communications

Anti-cancer peptides: classification, mechanism of action, reconstruction and modification

(2020) Mingfeng Xie et al.   Open Biology

Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion

(2020) Brian Koss et al.   CANCER RESEARCH

Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China

(2020) Yu Xia et al.   CURRENT GENE THERAPY

Tumor suppressor p53: from engaging DNA to target gene regulation

(2020) Morgan A Sammons et al.   NUCLEIC ACIDS RESEARCH

The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor

(2020) Yiren Xiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis

(2020) Yu Chen Feng et al.   Nature Communications

Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation

(2020) Otto Luiz Dutra Cerqueira et al.   Frontiers in Immunology

mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression

(2020) Ning Kon et al.   GENES & DEVELOPMENT

Opportunities and Challenges in Drug Development for Pediatric Cancers

(2020) Theodore W. Laetsch et al.   Cancer Discovery

Upregulation of 5′-terminal oligopyrimidine mRNA translation upon loss of the ARF tumor suppressor

(2020) Kyle A. Cottrell et al.   Scientific Reports

Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer

(2020) Shipeng He et al.   Acta Pharmaceutica Sinica B

The multiple mechanisms that regulate p53 activity and cell fate

(2019) Antonina Hafner et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network

(2019) Rana Elkholi et al.   MOLECULAR CELL

The molecular machinery of regulated cell death

(2019) Daolin Tang et al.   CELL RESEARCH

Targeting p53-MDM2 interaction using small molecule inhibitors and the challenges needed to be addressed

(2019) Maryam Zanjirband et al.   CURRENT DRUG TARGETS

Mechanistic basis for impaired ferroptosis in cells expressing the African-centric S47 variant of p53

(2019) Julia I-Ju Leu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53

(2019) Wei Wang et al.   CANCER LETTERS

Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics

(2019) Anabel Sorolla et al.   ONCOGENE

Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy

(2019) Boris Klimovich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metabolic landscape of the tumor microenvironment at single cell resolution

(2019) Zhengtao Xiao et al.   Nature Communications

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

(2018) Jo Ishizawa et al.   CANCER RESEARCH

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

(2018) Max D. Wellenstein et al.   IMMUNITY

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK2 Inhibitor for Treatment of Triple-negative Breast Cancer with a Compromised G1/S Checkpoint

(2018) Dan Zhu et al.   MOLECULAR CANCER THERAPEUTICS

Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53

(2018) Giuseppe Arena et al.   MOLECULAR CELL

CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response

(2018) Emma Haapaniemi et al.   NATURE MEDICINE

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia

(2018) Luis A. Carvajal et al.   Science Translational Medicine

P53 and mTOR signalling determine fitness selection through cell competition during early mouse embryonic development

(2018) Sarah Bowling et al.   Nature Communications

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

(2018) Agnieszka K. Witkiewicz et al.   Cell Reports

p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells

(2018) Amy Tarangelo et al.   Cell Reports

p53 and the Viral Connection: Back into the Future ‡

(2018) Ronit Aloni-Grinstein et al.   Cancers

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours

(2018) Xiaotu Ma et al.   NATURE

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

(2018) John Hines et al.   CANCER RESEARCH

Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects

(2018) Shruti Rastogi et al.   DRUG DISCOVERY TODAY

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

(2018) Yangbing Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mutant p53 sequestration of MDM2 acidic domain inhibits E3 ligase activity

(2018) Leixiang Yang et al.   MOLECULAR AND CELLULAR BIOLOGY

mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53

(2018) Seung Hee Jung et al.   ONCOGENE

Arginine-rich cell-penetrating peptides induce membrane multilamellarity and subsequently enter via formation of a fusion pore

(2018) Christoph Allolio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene

(2018) Xueqian Gong et al.   Cancer Discovery

Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival

(2018) Matthew G. Oser et al.   Cancer Discovery

Mitochondrial p32/C1qbp Is a Critical Regulator of Dendritic Cell Metabolism and Maturation

(2018) Kazuhito Gotoh et al.   Cell Reports

Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice

(2017) Lubing Gu et al.   MOLECULAR CANCER THERAPEUTICS

NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression

(2017) Delin Chen et al.   MOLECULAR CELL

The most popular genes in the human genome

(2017)   NATURE

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase

(2017) L E Giono et al.   ONCOGENE

p14ARF interacts with the focal adhesion kinase and protects cells from anoikis

(2017) M Vivo et al.   ONCOGENE

Census and evaluation of p53 target genes

(2017) M Fischer   ONCOGENE

Reviving the guardian of the genome: Small molecule activators of p53

(2017) Daniel Nguyen et al.   PHARMACOLOGY & THERAPEUTICS

Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects ofArftumor suppressor-deficient mice

(2017) Jolieke G. van Oosterwijk et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anatomy of Mdm2 and Mdm4 in evolution

(2017) Ban Xiong Tan et al.   Journal of Molecular Cell Biology

Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation

(2017) David S. Liu et al.   Nature Communications

Protection against High-Fat-Diet-Induced Obesity in MDM2 C305F Mice Due to Reduced p53 Activity and Enhanced Energy Expenditure

(2017) Shijie Liu et al.   Cell Reports

Conservation and Divergence of p53 Oscillation Dynamics across Species

(2017) Jacob Stewart-Ornstein et al.   Cell Systems

Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment

(2016) Lubing Gu et al.   CANCER CELL

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

(2016) Alice Soragni et al.   CANCER CELL

2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway

(2016) Jingwen Xu et al.   CANCER LETTERS

Peptide-based tumor inhibitor encoding mitochondrial p14ARFis highly efficacious to diverse tumors

(2016) Ken Saito et al.   CANCER SCIENCE

Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer

(2016) Anup Kumar Singh et al.   CARCINOGENESIS

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans

(2016) Cynthia R. Coffill et al.   GENES & DEVELOPMENT

An African-specific polymorphism in theTP53gene impairs p53 tumor suppressor function in a mouse model

(2016) Matthew Jennis et al.   GENES & DEVELOPMENT

The role of the p53 tumor suppressor in metabolism and diabetes

(2016) Che-Pei Kung et al.   JOURNAL OF ENDOCRINOLOGY

Rare cancers: a sea of opportunity

(2016) Niki Boyd et al.   LANCET ONCOLOGY

Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53

(2016) G. Karan et al.   MOLECULAR CANCER THERAPEUTICS

Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53

(2016) Romain Riscal et al.   MOLECULAR CELL

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction

(2016) Che-Pei Kung et al.   Cell Reports

Clinical Overview of MDM2/X-Targeted Therapies

(2016) Andrew Burgess et al.   Frontiers in Oncology

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway

(2016) Lioubov G. Korotchkina et al.   Aging-US

The MDM2 RING Domain and Central Acidic Domain Play Distinct Roles in MDM2 Protein Homodimerization and MDM2-MDMX Protein Heterodimerization

(2015) Patrick L. Leslie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TRIM28 Is an E3 Ligase for ARF-Mediated NPM1/B23 SUMOylation That Represses Centrosome Amplification

(2015) Shu Hui Neo et al.   MOLECULAR AND CELLULAR BIOLOGY

The p53 C Terminus Controls Site-Specific DNA Binding and Promotes Structural Changes within the Central DNA Binding Domain

(2015) Oleg Laptenko et al.   MOLECULAR CELL

Ferroptosis as a p53-mediated activity during tumour suppression

(2015) Le Jiang et al.   NATURE

Modulation of p53 during bacterial infections

(2015) Christine Siegl et al.   NATURE REVIEWS MICROBIOLOGY

Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf–Mdm2–p53 and RP–Mdm2–p53 pathways

(2015) X Meng et al.   ONCOGENE

PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence

(2015) Lisa Ivanschitz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation

(2015) Evrim Gurpinar et al.   TRENDS IN CELL BIOLOGY

Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells

(2015) W Wu et al.   Cell Death & Disease

Intracellular CD24 disrupts the ARF–NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation

(2015) Lizhong Wang et al.   Nature Communications

Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells

(2015) Simona Daniele et al.   Scientific Reports

Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation

(2015) Jianzhong Chen et al.   Scientific Reports

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

(2015) Sébastien Jeay et al.   eLife

BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function

(2015) Xuetian Yue et al.   eLife

A Small-Molecule p53 Activator Induces Apoptosis through Inhibiting MDMX Expression in Breast Cancer Cells

(2015) Hongbo Wang et al.   NEOPLASIA

ARF tumor suppression in the nucleolus

(2014) Leonard B. Maggi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Regulation of p53 by Mdm2 E3 Ligase Function Is Dispensable in Embryogenesis and Development, but Essential in Response to DNA Damage

(2014) Laura A. Tollini et al.   CANCER CELL

FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX

(2014) X. Ling et al.   CANCER RESEARCH

Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo

(2014) T J Phesse et al.   CELL DEATH AND DIFFERENTIATION

Role of p53 in Systemic Autoimmune Diseases

(2014) Hiroaki Takatori et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice

(2014) Wei Wang et al.   GASTROENTEROLOGY

Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition

(2014) P. Ye et al.   MOLECULAR AND CELLULAR BIOLOGY

Identification of TRIML2, a Novel p53 Target, that Enhances p53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes

(2014) Che-Pei Kung et al.   MOLECULAR CANCER RESEARCH

Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5

(2014) K Tago et al.   ONCOGENE

Inhibition of MDM2 by Nilotinib Contributes to Cytotoxicity in Both Philadelphia-Positive and Negative Acute Lymphoblastic Leukemia

(2014) Hailong Zhang et al.   PLoS One

Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation

(2014) Y. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility

(2014) Claus Christensen et al.   Nature Communications

ARF and p53 Coordinate Tumor Suppression of an Oncogenic IFN-β-STAT1-ISG15 Signaling Axis

(2014) Jason T. Forys et al.   Cell Reports

A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction

(2013) Anna Budina-Kolomets et al.   Autophagy

Potentially functional variants ofp14ARFare associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy

(2013) Xicheng Song et al.   CARCINOGENESIS

INK4a/ARF limits the expansion of cells suffering from replication stress

(2013) Angela Monasor et al.   CELL CYCLE

A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings

(2013) Jianzhong Chen et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Antitumor Impact of p14ARF on Gefitinib-Resistant Non-Small Cell Lung Cancers

(2013) K. Saito et al.   MOLECULAR CANCER THERAPEUTICS

ARF Represses Androgen Receptor Transactivation in Prostate Cancer

(2013) Wenfu Lu et al.   MOLECULAR ENDOCRINOLOGY

The ARF tumor-suppressor controls Drosha translation to prevent Ras-driven transformation

(2013) M J Kuchenreuther et al.   ONCOGENE

Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis

(2013) A. I. Nieminen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets

(2013) Ana Rita Carlos et al.   Nature Communications

Stapled Peptides with Improved Potency and Specificity That Activate p53

(2012) Christopher J. Brown et al.   ACS Chemical Biology

A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2

(2012) Kai-Wei Hsueh et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers

(2012) Pavlina Dolezelova et al.   CELL CYCLE

A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53

(2012) Qi Zhang et al.   EMBO Molecular Medicine

p14ARF-induced Apoptosis in p53 Protein-deficient Cells Is Mediated by BH3-only Protein-independent Derepression of Bak Protein through Down-regulation of Mcl-1 and Bcl-xLProteins

(2012) Annika Müer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53–MDM2 Protein–Protein Interaction

(2012) Chunlin Zhuang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells

(2012) Oliver D. K. Maddocks et al.   NATURE

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

(2012) B. Graves et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

p53 Dynamics Control Cell Fate

(2012) J. E. Purvis et al.   SCIENCE

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Interaction of the ARF tumor suppressor with cytosolic HSP70 contributes to its autophagy function

(2011) Julia Pimkina et al.   CANCER BIOLOGY & THERAPY

The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

(2011) Stian Knappskog et al.   CANCER CELL

p53 Binds to and Is Required for the Repression of Arf Tumor Suppressor by HDAC and Polycomb

(2011) Y. Zeng et al.   CANCER RESEARCH

RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis

(2011) A. J. Saporita et al.   CANCER RESEARCH

MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity

(2011) Maren H. Stindt et al.   CELL CYCLE

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

The evolution of MDM2 family genes

(2011) Jamil Momand et al.   GENE

Hypergrowth mTORC1 Signals Translationally Activate the ARF Tumor Suppressor Checkpoint

(2011) A. P. Miceli et al.   MOLECULAR AND CELLULAR BIOLOGY

The ARF Tumor Suppressor Inhibits Tumor Cell Colonization Independent of p53 in a Novel Mouse Model of Pancreatic Ductal Adenocarcinoma Metastasis

(2011) V. P. Muniz et al.   MOLECULAR CANCER RESEARCH

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

(2011) D. Li et al.   MOLECULAR CANCER RESEARCH

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

(2011) Gina M. DeNicola et al.   NATURE

The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo

(2011) L. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors

(2011) A V Vaseva et al.   Cell Death & Disease

Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay

(2011) A. G. Herman et al.   Cancer Discovery

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

(2010) Federico Bernal et al.   CANCER CELL

An ARF-Independent c-MYC-Activated Tumor Suppression Pathway Mediated by Ribosomal Protein-Mdm2 Interaction

(2010) Everardo Macias et al.   CANCER CELL

A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development

(2010) Sean M. Post et al.   CANCER CELL

ARF Suppresses Tumor Angiogenesis through Translational Control of VEGFA mRNA

(2010) Hiroyuki Kawagishi et al.   CANCER RESEARCH

Mdm2 and p53 are highly conserved from placozoans to man

(2010) David P. Lane et al.   CELL CYCLE

S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response

(2010) Keng Po Lai et al.   EMBO JOURNAL

Turning the RING Domain Protein MdmX into an Active Ubiquitin-Protein Ligase

(2010) Saravanakumar Iyappan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification and Characterization of the First Small Molecule Inhibitor of MDMX

(2010) Damon Reed et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MDM2 Mediates Ubiquitination and Degradation of Activating Transcription Factor 3

(2010) Pingli Mo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Arf tumor suppressor protein inhibits Miz1 to suppress cell adhesion and induce apoptosis

(2010) Barbara Herkert et al.   JOURNAL OF CELL BIOLOGY

Mitochondrial p32 Protein Is a Critical Regulator of Tumor Metabolism via Maintenance of Oxidative Phosphorylation

(2010) V. Fogal et al.   MOLECULAR AND CELLULAR BIOLOGY

A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

(2010) H. Wang et al.   MOLECULAR CANCER THERAPEUTICS

The ARF Tumor Suppressor Controls Ribosome Biogenesis by Regulating the RNA Polymerase I Transcription Factor TTF-I

(2010) Frédéric Lessard et al.   MOLECULAR CELL

An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis

(2009) R C Kovi et al.   CELL DEATH AND DIFFERENTIATION

p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug

(2009) Shu-Ping Wang et al.   NATURE CELL BIOLOGY

p53 represses c-Myc through induction of the tumor suppressor miR-145

(2009) M. Sachdeva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mitochondrial p32 Is a Critical Mediator of ARF-Induced Apoptosis

(2008) Koji Itahana et al.   CANCER CELL

p53-Dependent and p53-Independent Activation of Autophagy by ARF

(2008) W. M. Abida et al.   CANCER RESEARCH

The ARF Tumor Suppressor Can Promote the Progression of Some Tumors

(2008) O. Humbey et al.   CANCER RESEARCH

Acetylation Is Indispensable for p53 Activation

(2008) Yi Tang et al.   CELL

p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling

(2008) Andrei V. Budanov et al.   CELL

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

(2008) T. Terzian et al.   GENES & DEVELOPMENT

ARF Induces Autophagy by Virtue of Interaction with Bcl-xl

(2008) Julia Pimkina et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

(2008) K Kojima et al.   LEUKEMIA

Nucleophosmin Serves as a Rate-Limiting Nuclear Export Chaperone for the Mammalian Ribosome

(2008) L. B. Maggi et al.   MOLECULAR AND CELLULAR BIOLOGY

Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines

(2008) Eisaku Kondo et al.   MOLECULAR CANCER THERAPEUTICS

Characterization of a Novel Cytotoxic Cell‐penetrating Peptide Derived From p14ARF Protein

(2007) Henrik J Johansson et al.   MOLECULAR THERAPY